Clinical trials: for Brain Tumors
Epilepsy; Seizure
ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors
Phase 2A single-arm exploratory clinical study in up to 12 adult subjects aged 18 and older with primary glioma, IDH1 mutation, and uncontrolled focal-onset seizure activity to determine the potential efficacy, safety and…
- Trial name
- NCT04737174
- Testing
- ES-481
- Sponsor
- ES Therapeutics Australia Pty Ltd
Low-Grade Gliomas, Malignant Neoplasms, Brain
Study of MEK162 for Children With Low-Grade Gliomas
The goal of this clinical trial is to study the drug MEK162 in children with a brain tumor call low-grade glioma, as well as in children with other tumors in which a specific growth signal is abnormally turned on.
- Conditions
- Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
- Trial name
- NCT02285439
- Testing
- MEK162
- Where
- 15 sites in United States
- Volunteers
- 105 people
- Sponsor
- Children's Hospital Los Angeles
Multiple Sclerosis, Transverse Myelitis
Biobank For MS And Other Demyelinating Diseases
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated…
- Conditions
- Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis
- Trial name
- NCT00445367
- Where
- 10 sites in United States
- Volunteers
- 3,226 people, healthy volunteers welcome
- Sponsor
- Accelerated Cure Project for Multiple Sclerosis
Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as vinblastine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352495
- Testing
- carboplatin, vinblastine sulfate
- Where
- 21 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Multiple Brain Metastases
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain…
- Trial name
- NCT03608020
- Testing
- BMX-001, Whole Brain Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- BioMimetix JV, LLC
Glioma
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
The main purpose of this study is to assess the effect of a two-week pre-surgery treatment with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid) methyltransferase (MGMT) activity in patients…
- Trial name
- NCT00424554
- Testing
- temozolomide
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioma, Glioneuronal Tumor
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on…
- Conditions
- Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
- Trial name
- NCT05259605
- Testing
- Observational
- Where
- 42 sites in Austria, Belgium and 10 more
- Volunteers
- 1,650 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cognitive Impairment, Haematological Malignancy
Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies
BACKGROUND Neurocognitive symptoms have a high prevalence in cancer patients, resulting in a significant impact on daily life and tolerance to therapy.
- Conditions
- Cognitive Impairment, Haematological Malignancy, Chemo-brain
- Trial name
- NCT04673305
- Testing
- Cognitive Assessment, Cytokine dosage
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Ospedale San Carlo Borromeo
Brain Tumors, Quality of Life
Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing
Background. Survivors of childhood brain tumours have the poorest health-related quality of life of all cancer survivors due to the multiple physical and psychological sequelae of brain tumours and their treatment.
- Conditions
- Brain Tumors, Quality of Life, Brain Tumor, Pediatric
- Trial name
- ACT NOW (NCT04722237)
- Testing
- Acceptance and Commitment Therapy
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Cancer, Brain Metastases
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
The protocol is designed to determine the efficacy of temozolomide in preventing the development of new brain metastases within the first year in patients undergoing stereotactic radiation for newly diagnosed brain metastases.
- Trial name
- RAD0102 (NCT00582075)
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Oncology, DIPG
xPedite: A Study to Expedite DIPG and DMG Research
This study will gather data from new and existing patients with patient medical records, and patient/family/caregiver reported information to establish a clear natural history of disease suitable to serve as an external…
- Conditions
- Oncology, DIPG, DMG
- Trial name
- NCT06140719
- Where
- United States
- Sponsor
- xCures
Metastatic Intracranial Malignant Neoplasm, Recurrent Intracranial Neoplasm
18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain
This phase I trial studies the ability and amount of fluciclovine positron emission tomography (PET) imaging needed to recognize tumors that have come back (recurrence) after brain injury from radiation therapy (radionecrosis) in…
- Trial name
- NCT04462419
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography, Fluciclovine F18
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Childhood Cancer, Childhood Solid Tumor
PRecISion Medicine for Children With Cancer
This is a multicentre prospective study of the feasibility and clinical value of a diagnostic service for identifying therapeutic targets and recommending personalised treatment for children and adolescents with high-risk cancer.
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Childhood Leukemia
- Trial name
- PRISM (NCT03336931)
- Testing
- Molecular profiling and drug testing
- Where
- 8 sites in Australia
- Volunteers
- 550 people
- Sponsor
- Sydney Children's Hospitals Network
Neurologic Disorder, Stroke
Home Based Tele-exercise for People With Chronic Neurological Impairments
To assess the impact of a 12-week virtual seated physical intervention on cardiovascular health and wellness in people with chronic neurological impairments (CNI).
- Conditions
- Neurologic Disorder, Stroke, Spinal Cord Injuries, Cerebral Palsy
- Trial name
- Telex (NCT04564495)
- Testing
- Seated exercise
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Burke Medical Research Institute
Long Term, Hypopituitarism
Long-Term Outcomes of Hypopituitarism Following Gamma Knife Radiosurgery for Pituitary Adenomas
This study aims to assess long-term outcomes of hypopituitarism following gamma knife radiosurgery (GKRS) for pituitary adenomas.
- Conditions
- Long Term, Hypopituitarism, Gamma Knife Radiosurgery, Pituitary Adenomas
- Trial name
- NCT07015645
- Testing
- Gamma Knife Radiosurgery
- Where
- Egypt
- Volunteers
- 137 people
- Sponsor
- Al-Azhar University
Triple Negative Breast Cancer, Brain Metastases
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
The study is a phase II with safety lead in, single arm, study using Nal-IRI in combination with pembrolizumab. Nal-IRI will be given IV every 2 weeks starting at 50mg/m2. Pembrolizumab will be given 400mg IV every 6 weeks.
- Trial name
- NCT05255666
- Testing
- Pembrolizumab, Liposomal Irinotecan
- Sponsor
- Washington University School of Medicine
Cushing Syndrome, Cushing Disease
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an…
- Conditions
- Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
- Trial name
- NCT05804669
- Testing
- atumelnant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Cutaneous Melanoma, Brain Metastases
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of…
- Trial name
- DETERMINE (NCT06194929)
- Testing
- Defactinib, Avutometinib, Encorafenib
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Utah
Brain and Central Nervous System Tumors, Metastatic Cancer
CCI-779 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003712
- Testing
- temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
High Grade Glioma, Meningioma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET.
- Conditions
- High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma
- Trial name
- NCT05278208
- Testing
- LUTATHERA® (Lutetium Lu 177 dotatate)
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Nationwide Children's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.